首页> 美国卫生研究院文献>other >PET/CT Scanner and Bone Marrow Biopsy in Detection of Bone Marrow Involvement in Diffuse Large B-Cell Lymphoma
【2h】

PET/CT Scanner and Bone Marrow Biopsy in Detection of Bone Marrow Involvement in Diffuse Large B-Cell Lymphoma

机译:PET / CT扫描仪和骨髓活检检查弥漫性大B细胞淋巴瘤的骨髓受累情况

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Evaluation of bone marrow involvement (BMI) is paramount in diffuse large B-cell lymphoma (DLBCL) for prognostic and therapeutic reasons. PET/CT scanner (PET) is now a routine examination for the staging of DLBCL with prognostic and therapeutic implications. This study evaluates the role of PET for detecting marrow involvement compared to bone marrow biopsy (BMB). This monocentric study included 54 patients diagnosed with DLBCL between 2009 and 2013 and who had FDG PET/CT in a pre-treatment setting. A correlation analysis of the detection of BMI by PET and BMB was performed. A prognostic evaluation of BMI by BMB and/or PET/CT and correlation with an overall 2-year survival were analyzed. PET was more sensitive for the detection of BMI than BMB (92.3% vs. 38.5%). It can be considered a discriminatory Pre-BMB test with a negative predictive value of 97.6%. In addition, BMI by PET had a prognostic value with strong correlation with progression-free survival (PFS) (HR = 3.81; p = 0.013) and overall survival (OS) (HR = 4.12; p = 0.03) while the BMB had not. PET shows superior performance to the BMB for the detection of marrow involvement in DLBCL. It may be considered as the first line examination of bone marrow instead of the biopsy.
机译:对于弥漫性大B细胞淋巴瘤(DLBCL),由于预后和治疗原因,评估骨髓受累(BMI)至关重要。 PET / CT扫描仪(PET)现在是DLBCL分期的常规检查,具有预后和治疗意义。这项研究评估了PET与骨髓活检(BMB)相比在检测骨髓受累中的作用。这项单中心研究纳入了54位在2009年至2013年期间诊断为DLBCL且在治疗前接受过FDG PET / CT的患者。对PET和BMB检测BMI进行了相关分析。分析了BMB和/或PET / CT对BMI的预后评估以及与总体2年生存率的相关性。 PET对BMI的检测比BMB更为敏感(92.3%对38.5%)。可以将其视为具有歧视性的Pre-BMB测试,其阴性预测值为97.6%。此外,PET的BMI具有与无进展生存期(PFS)(HR = 3.81; p = 0.013)和总生存期(OS)(HR = 4.12; p = 0.03)密切相关的预后价值,而BMB没有。 PET在检测DLBCL中的骨髓受累方面显示出优于BMB的性能。它可能被认为是骨髓的一线检查,而不是活检。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号